Another approach is to utilize CD40 agonists to program tumor-associated macrophages to a less immunosuppressive status, ultimately leading to CD8 T cell infiltration with possible implications for more successful immunotherapy options [26,27,183]. The gene discussed is CD8A; the disease is neoplasm.